At a glance
ClinicalIndex Comparison RecordN/ACompleted· 2,000 enrolled
Drug / intervention
No interventionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV
In Brief
An observational study evaluating No intervention for Monkeypox and HIV Coinfection. Completed, enrolled 2,000 participants across 9 sites in 4 countries.
Detailed Summary
This data collection study aims to describe and compare the outcomes of Mpox on people living with HIV (PLHIV) and HIV-negative individuals who are on pre-exposure prophylaxis (PrEP). The study also aims to identify risk factors for specific Mpox outcomes.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMonkeypox, HIV Coinfection
CountriesFrance, Poland, Spain, United Kingdom
CollaboratorsEuropean Commission, PENTA Foundation
Timeline
N/ACompletedFinished
202420252026
First PostedJul 2023
Enrollment StartDec 2023
Primary CompletionMay 2025
TodayJul 2026
First PostedJul 28, 2023
Enrollment StartDec 1, 2023
Primary CompletionMay 7, 2025
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 2.9 years ago
Interventions
No interventionother
Study is retrospective data collection only